Insilico Medicine and SK Biopharmaceuticals announced an AI-enabled drug discovery collaboration focused on neuroimmune disorders, with deal economics potentially exceeding $2.5 billion. The agreement centers on using AI search capabilities to identify and develop candidates for targets linked to neuroimmune pathways. The size and backloaded structure point to long-horizon expectations for translational performance, with value tied to clinical and regulatory milestones. For the AI drug discovery space, the partnership reinforces that platform-driven candidate generation is increasingly being underwritten by major pharma-linked balance sheets. As neuroimmune disease remains a complex therapeutic area, the collaboration also signals that both parties see enough target and modality potential to justify scaling efforts beyond discovery into development planning.